Genetic characterization of individuals at risk of Alzheimer's disease (AD), i.e. people having amyloid deposits in the brain without symptoms, people suffering from subjective cognitive decline (SCD) or mild cognitive impairment (MCI), has spurred the interests of researchers. However, their pre-dementia genetic profile remains mostly unexplored. In this study, we reviewed the loci related to phenotypes of AD, MCI and SCD from literature and performed the first meta-analyses evaluating the role of apolipoprotein E (APOE) in the risk of conversion from a healthy status to MCI and SCD. For AD dementia risk, an increased number of loci have been identified; to date, 28 genes have been associated with Late Onset AD. In MCI syndrome, APOE is confirmed as a pheno-conversion factor leading from MCI to AD, and clusterin is a promising candidate. Additionally, our meta-analyses revealed APOE as genetic risk factor to convert from a healthy status to MCI [OR = 1.849 (1.587-2.153); P = 2.80 × 10
Introduction
Although Alzheimer's disease (AD) is mainly diagnosed in the elderly, its pathophysiological processes begin several years prior to the onset of symptoms (Ref. 1) .
Clinical AD is preceded by a long asymptomatic period, which has been divided into three stages: (1) an initial preclinical stage, (2) a second mild, but progressive, cognitive impairment (MCI) and (3) the final stage of clinical dementia due to AD (Refs 1, 2, 3). Recently, researchers have increasingly focused on the characterisation of stages of AD risk, as these provide a critical opportunity for potential intervention (Ref. 1) .
With ageing, there is a natural decline in cognitive skills. Thus, it may be difficult to discriminate between early cognitive changes due to AD and normal ageing process (Ref. 4) . In that context, the first evidence of dementia may be the subjective cognitive decline (SCD), defined as a self-reported memory impairment with normal cognitive performance (Ref. 5 ). Complainers present a higher rate of conversion of SCD to either MCI or dementia (Ref. 6) . Thus, epidemiological studies pointed SCD as a predictor of cognitive decline (Refs 7, 8) and as an independent risk factor for dementia (Ref. 9) . In succession, the prodromal stage of dementia, MCI, has been defined as memory impairment beyond that expected for normal ageing (Ref. 10) . Several MCI phenotypes have been associated with AD progression (Ref. 11); however, amnestic MCI (aMCI) confers a higher risk of conversion (Ref. 11) .
The identification of MCI subjects, or even SCD who will convert to MCI or dementia, puts across an interesting strategy for secondary prevention of AD. In that sense, the biomarkers of β-amyloidosis and tau-mediated neuronal injury are detected in subjects with normal cognition (Ref. 12) . However, these biomarkers are not sufficient to produce the clinical symptoms of MCI and dementia or are not specific to AD either (Ref. 1) . Furthermore, these biomarkers are not sensitive to disease progression (Ref. 13) . Hence, new approaches are required to improve the differentiation of SCD or MCI converters to AD.
AD's genetics has gained much attention since AD presents a heritability of up 70% (Ref. 14) . Recently, researchers have been striving towards the identification of new AD's genetic risk factors. In that sense, the identification of a genetic risk profile for predementia stages may prove to be a powerful approach to select the candidate subjects to prevent or delay the disease progression during the early preclinical stages. If a fraction of SCD and MCI patients are in the pre-AD stages, the identification of an increased number of AD risk alleles as well as that of additional genetic factors specifically influencing SCD or MCI progression can be expected.
In this work, we reviewed the available information in the literature for genome-wide significant variants associated with AD and their involvement in preclinical, prodromal and dementia stages of AD. Additionally, we provide new meta-analysed data for apolipoprotein E (APOE) ε4 in preclinical and prodromal stages.
Methods: meta-analysis Meta-analysis was performed for exploring the role of APOE ε4 in: (1) risk of MCI and (2) risk of SCD.
Dataset selection
Literature search was conducted in PubMed (http:// www.ncbi.nlm.nih.gov/pubmed/) using the following keywords: (1) for MCI: APOE, genetics, risk, mild cognitive impairment and excluding reviews; and (2) for SCD: APOE, SCD. A total of 301 articles were found for MCI and 32 for SCD.
We selected the studies meeting the following criteria: (1) case/control studies or longitudinal studies where it is possible to distinguish a sub-population of cases and a sub-population of controls; (2) studies that provide a complete definition of the participants; (3) studies that evaluated the APOE ε4 genotype as a risk factor leading to MCI or SCD, or provided the numbers of APOE ε4 genotypes or provided sufficient data to calculate them; and (4) studies that provided an odds ratio (OR) with 95% confidence interval (CI) as well as the P-value or provide sufficient data to calculate them. Finally, of the 301 articles found for MCI, 207 did not follow inclusion criteria, 29 showed sample overlapping and 41 had restricted access. A total of 24 articles and 23 668 individuals on MCI were finally included. In the case of SCD, 21 of the 32 articles did not follow the inclusion criteria and 3 showed sample overlapping; finally, a total of 8 articles and 6824 individuals were included in the meta-analysis.
Meta-analysis
Meta-analysis was conducted using the inverse variant method (fixed-effects model) in Ephisheet Excel application. In the case of heterogeneity, DerSimonian and Liard method (random-effects model) was used. Heterogeneity was considered significant when I 2 > 50% and P < 0.05. Meta-analysis results and forest plots were obtained using OpenMeta.
Dementia stage: genetic risk factors of AD AD is a genetically heterogeneous disorder. From a genetic point of view, two patterns of inheritance have been linked to the genomic loci: the autosomal dominant and the polygenic. Traditionally, these patterns have been associated with early and late onset forms of the disease, respectively. However, based on the family history, AD can be subdivided into autosomal dominant, familial and sporadic (Ref. 15 ).
Autosomal dominant AD
The familial autosomal dominant pattern in AD represents ∼1% of all the AD cases and is found almost exclusively in early onset AD (EOAD) (Ref. 15) . It occurs in at least three individuals in two or more generations, with two of the individuals being first-degree relatives of the third (Ref. 15 ).
Linkage and candidate gene studies in EOAD families led to the identification of disease-causing mutations in β-amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes ( Refs 16, 17, 18) . Most frequent mutations are shown in PSEN1 and APP loci, respectively, which present complete penetrance in contrast to PSEN2, which presents 95% penetrance (Ref. 15) . These identifications promoted the formulation of amyloid cascade hypothesis, which is still considered as a possible disease mechanism. Despite that, there are EOAD families with negative screening for APP, PSEN1 and PSEN2 mutations supporting the existence of additional causal genes (Ref. 19 ). In addition, it is seen that APOE ε4 genotype, the major genetic risk factor for Late-Onset Alzheimer's disease (LOAD) (Ref. The commonest AD phenotype, LOAD The genetic and molecular basis for the commonest AD phenotype, i.e. LOAD, remains widely unknown. However, important progress on the isolation of the loci associated with AD has been achieved in the past few years because of the emergence of the genomewide association (GWAS) and exome studies.
The ε4 allele of the APOE gene was the first genetic variant associated with LOAD (Ref. 20) , and it remains as the major risk factor for the disease until now.
Behind the APOE discovery, the candidate gene approach led to the identification of two clusters of single nucleotide polymorphisms (SNPs) Despite that, the GWAS approach presented a disadvantage, i.e. its inability to detect rare variants, which might be a source of functional variants with larger effects on the LOAD risk (Ref. 38) . This lack was covered by the implementation of genome and exome sequencing technologies. Thus, in the recent years, rare variants with a significant effect on the risk for LOAD have been identified in APP, TREM2, PDL3 and UNC5C loci (Refs 38, 39, 40, 41). However, more efforts are needed to confirm the original signals. Several studies have confirmed the reported association of TREM2 with LOAD (Refs 42, 43). In addition, the existence of TREM2 variants associated with the Naso-Hakola disease (Ref. 44 ) and frontotemporal dementia (Ref. 45 ) supports its role in neurodegeneration. Alternatively, the PLD3 variants' replication did not replicate the previous effect or overall burden analyses (Refs 46, 47). Therefore, prudence is required to define the genuine signals associated with rare variants.
At present, 28 genetic regions have been associated with LOAD (Table 1 ), but many of them still require independent validation. These genes can be divided into four major functional clusters: (i) amyloid beta (Aβ) metabolism (APOE, CLU, ABCA7, CASS4, SORL1 and APP), (ii) Tau metabolism (BIN1, SLC2A4A-RIN1, CASS4, FERMT2 and 17q21.31 MAPT region), (iii) synaptic function (PICALM, CD2AP, EPHA1, SLC2A4A-RIN1, MEF2C and ZCWPW1) and (iv) immune response and inflammation (CLU, CR1, EPHA1, MS4A cluster, ABCA7, HLA-DRB5-HLA-DRB1, INPP5; MEF2C, TREM2 and IGHV1-67). Seven identified loci do not have a well-established pathway (PTK2B, CELF1, NME8, TRIP4, ATP5H/KCTD2, UNC5C and TP53INP1) (Fig. 1) .
Along with the identification of single locus, GWAS also permits the genetic confirmation of candidate pathways. Recently, pathway analysis studies have pointed toward the crucial role of the immune system in AD (Ref. 48) , that has been further reinforced by the IGAP results (Ref. 49) . Moreover, the IGAP study also implicates the regulation of endocytosis, cholesterol transport and protein ubiquitination as prime targets in the aetiology of AD (Ref. 49) . The knowledge of the biological pathways involved in disease aetiology is crucial in the development of therapeutic strategies to aid in the prevention or treatment of LOAD.
Prodromal stage: genetics of mild cognitive impairment syndrome APOE genotype in MCI Petersen et al. (Ref. 50) were the first to provide evidence that MCI subjects with at least one allele of APOE ε4 presented a higher probability of conversion to dementia. Although subsequent genetic studies supported it (Refs 51, 52), they had small sample sizes, which only succeeded in providing an approximate value of the risk effect (Ref. 53) . Thus, the metaanalysis conducted by Elias-Sonnenschein et al. (Ref. 54) provided the first consistent data corroborating the role of APOE ε4 as a genetic risk factor for progression from MCI to AD ( Table 2) .
The involvement of APOE ε4 as a risk factor for MCI remains less explored. Therefore, here we have explored the risk conferred by APOE ε4 genotype to suffer MCI. Our meta-analysis, which includes 23 668 individuals of different ethnic groups, confirmed a significant risk association of APOE ε4 genotype and MCI [OR = 1.849 (1.587-2.153)] (Fig. 2) ( Table 2 ). Our dataset showed high heterogeneity (I 2 = 63%; P-value < 0.001). In that sense, sub-population study revealed higher heterogeneity for Caucasian dataset with respect to Asiatic group (I 2 = 68%; P-value < 0.001; I 2 = 51%, P-value = 0.104). It must be considered that the major number of available studies is provided for Caucasians. Additionally, several studies have shown that the risk is higher for aMCI subpopulation in comparison with the rest of the MCI subtypes (Ref. 55) ( Table 2 ). This makes sense in the context of MCI as the prodromal stage of AD.
Although most of the attention has been focused on the risk allele ε4 of APOE, the ε2 allele has also demonstrated its role in AD (Ref. Non-APOE LOAD loci in MCI Apart from APOE, the genome-wide significant variants for LOAD in MCI population remain largely unknown. However, in the past few years, several studies have pointed out their influence in cognitive decline. Thus, CR1 and ABCA7 genes have been associated with faster rate of cognitive decline (CR1 P-value = 0.011; ABCA7 P-value = 0.013) (Refs 61, 62). EPHA1 and PICALM loci were also associated with faster and slower rate of decline (EPHA1 P = 0.013; PICALM P = 0.027), respectively, however they did not support Bonferroni corrections (Ref. 63) . Following studies for EPHA1 only replicated it marginally (P = 0.05) (Ref. 62) . Finally, the CLU locus was associated with cognitive endophenotypes in several studies. In that sense, the CLU risk allele has been associated with a faster rate of decline in some neuropsychological characteristics such as verbal immediate (P = 0.0032) and delayed free recall (P = 0.032) (Ref. 64 ) and its protective allele with a decreased risk of conversion to AD [OR = 0.25 (0.07-0.84), P = 0.025] (Ref. 65) . A study that evaluated the progression of normal subjects (n > 2000) to MCI/ LOAD pointed the significant effect of CLU on logical memory delayed recognition (LMDR) (coefficient for LMDR = −0.51 (−0.92 to −0.11, P = 0.012) (Ref. 62) . It further showed a borderline significant hazard ratio (HR) in the sensitivity analysis between CLU risk allele and the risk of progression from MCI to AD (HR = 1.10, P = 0.13; sensitivity HZ = 1.14, P = 0.049) (Ref. 62) . Recently, another experiment conducted on 3326 MCI subjects of four Genes by pathways associated with subjective cognitive decline (SCD), mild cognitive impairment (MCI) and clinical Alzheimer's disease (AD) and representation of level of genetic information at each stage. Genetic information response to the number of articles (n) found in the PubMed database with the keywords: Alzheimer's disease and genetics; mild cognitive impairment and genetics; subjective cognitive decline and genetics. Circular ideogram was performed using Circos (Ref. 120 ).
* Not replicated in follow-up studies or in International Genomics Alzheimer's Project (IGAP). Table 2) . Most of the identified LOAD loci present small risk effects and are, therefore, not quite informative for risk prediction on their own (Ref. 65) . Consequently, it is apprehended that the use of the genetic risk score (GRS) strategy, where multiple loci with modest effects are combined, might improve the identification of people at risk for common diseases (Ref. 65) . It was observed that MCI carriers of six or more non-APOE LOAD risk alleles showed rapid conversion to AD (Ref. 65) . However, in another study, the significant effect was only reached when the APOE genotype was considered (HR = 1.29, P = 1.14 × 10 ; sensitivity HR = 1.32, P = 5.73 × 10 −10 ) (Ref. 62) . In a recent study, GRS for 19 LOAD loci with genome-wide significance was associated with MCI (OR = 1.15, P = 0.011) and with progression from MCI to dementia (HR = 1.59, P < 0.001) (Ref. 66) .
With the exception of the APOE and CLU variants, it seems difficult to arrive at a conclusion about the role of LOAD SNPs in the context of MCI. Studies developed in larger cohorts are needed to check and validate the expected association between the LOAD risk genetic variants and MCI.
New loci associated with MCI It has been observed that additional loci have been associated with MCI. Recently, a GWAS associated rs12752888 (ACOT11 gene), rs7840202 (UBR5 -RRM2B region) and rs11637611 (unknown gene) markers with MCI progression (Ref. 63) (Table 2) . However, establishing a relationship with the present pathophysiological hypothesis of AD, at this stage, seems complex. Consequently, these signals require validation if they were to be discarded as false positive and either to be accepted as factors responsible for MCI progression.
Alternatively, candidate gene studies have suggested several aspirant genes associated with the pheno-conversion of MCI to AD. One such example is the MAPT gene. Specifically, a study revealed that the H1/H1 haplotype carriers presented a higher conversion rate of MCI to dementia (Ref. 67 Table 2 ). Since none of these genes have been validated for LOAD, it can be said that they may act as genetic progression factors. They are capable of modulating the rate of decline but are not involved in the risk leading to AD.
Preclinical stage: SCD
There is limited research on the genetic variants that determine the risk to SCD or the progression of SCD to MCI or AD. Therefore, we have conducted the first meta-analysis exploring the involvement of APOE ε4 in the risk to suffer SCD. A significant risk effect was detected [OR = 1.151 (1.015-1.304)] (Fig. 2) (Table 2) , with a borderline non-significant heterogeneity (I 2 = 46%, P-value = 0.075), which remains when the analysis is only performed for Caucasians (I 2 = 48%, P-value = 0.087). However, this significant association disappears [OR = 1.158 (0.933-1.437); P = 0.184] when a random model is used to conduct the meta-analysis. From our point of view, these results must be taken with prudence. SCD individuals represent a mixed population, where a pool of subjects may develop dementia, not exclusively AD and others never develop it. Hence, the sample size needed to detect Alzheimer's genuine genes must be larger.
Apart from the APOE ε4 polymorphism, other markers have been investigated to assess their possible association with SCD, such as alpha-2 macroglobulin gene (Ref. The genetic profile of the SCD subjects is unexplored in spite of the fact that its analysis could provide new ways to manage the disease. The generation of large SCD datasets integrating genomic information with follow-up data would be an essential step in identifying genetic elements responsible for the progression of SCD to MCI and AD.
Other approaches: endophenotype-based approach The use of quantitative traits closely related to the disease state, namely, endophenotypes, has been proposed as a simpler way to deal with genetic testing of LOAD. Thus, several endophenotypes have emerged across the cognitive spectrum of AD. Amyloid-β and tau levels in cerebrospinal fluid (CSF) CSF levels of Aβ42 and pTau181 have also been used as LOAD endophenotypes. APOE locus has been associated with both Aβ42 ( Refs 93, 94, 95) There is an inverse correlation between brain amyloid burden and Aβ CSF levels (Ref. 99) . From our understanding, both techniques are dealing with the same pathological process, Aβ deregulation. In that scenario, the identification of the following two might be expected: (1) the same genetic factors independently of the analysed quantitative trait and (2) the reported LOAD loci associated with Aβ metabolism. Available data seem to be too far of these requisites, with the exception of APOE, the most consistent across studies and across AD stages. Therefore, from our view, an unsuited sample size affecting statistical power or the use of the incorrect endophenotypes of AD could be preventing new discoveries.
Brain genetic resistance factors: studies in healthy people
The presence of Alzheimer-type pathology in healthy elderly people at death (Ref. 100) evidenced the existence of compensatory mechanisms avoiding a cognitive decline in populations. A GWAS developed in this group of subjects suggested the involvement of the RELN in the compensatory mechanism for AD (Ref. 101) and illustrated that studies on non-demented subjects with AD neuropathology are an interesting starting point to identify brain genetic resistance factors.
The state of resistance to brain insults, where the neuropathological hallmarks without clinical AD existing, has been defined as the cognitive reserve (CR Recently, two studies conducted on non-demented elderly subjects have showed that genes related to AD (TOMM40, APOE, MEF2C and ABCG1) are significantly associated with the cognitive function (Refs 113, 115) . This suggests that genes involved in the normal and pathological cognitions somehow overlap (Ref. 115 ) and highlight the applicability of the studies performed on healthy people. In addition, the cognition status has also been related to differential brain volumes (Ref. 116 ), thus, it seems that the HCV is a key component of the neuroanatomical basis of CR against memory in multiple sclerosis (Ref. 117) . Thus, although the existence of a genetic component influencing cognition is evident, its relevance in the health and disease processes remains unclear. However, it cannot be denied that its knowledge can bring new insights.
Either way, the investigation of genetic variants affecting cognition and brain structure in healthy people with and without AD neuropathology could be a starting point to determine the intrinsic genetic resistance to dementia. The information obtained through these studies must be comprehensively translated to evaluate its clinical utility in the preclinical stages of AD.
Conclusion
There exists an increasing interest in the characterization of the stages of pre-dementia. Taking into account the high genetic component of AD (Ref. 14) , the identification of genetic variants influencing MCI and SCD can provide a new perspective in tackling the disease.
Recent technological improvements have promoted the identification of 28 genetic variants for LOAD. Despite that, data concerning pre-dementia stages remain scarce. At present, APOE gene is the most consistent association with risk to MCI and progression from MCI to AD (Ref. 54) . The CLU locus has also showed promising results (Ref. 60) . There are more inconsistent data for SCD. To the best of our knowledge, we are the first to show meta-analysed data evidencing the role of APOE as a risk factor for SCD (Fig. 2) .
There is highly pronounced absence of genetic data for pre-dementia stage (Fig. 1) . In addition, there is a high degree of heterogeneity between available studies in pre-dementia stage. In an extended way, the MCI studies show a statistical correlation between the genotype and neuropsychological test scores, which mainly provides informative data. In most cases, studies with SCD and MCI individuals have small sample sizes. Moreover, the consideration of population characteristics seems pertinent. SCD and MCI individuals comprise highly heterogeneous population, where converters to AD dementia coexist with converters to other forms of dementia and non-converters. In that scenario, the identification of novel and expected LOAD loci may be hampered by the effect size of the true AD group. That could explain the reduction in the effect size of APOE along stages. On the other hand, the identification of progression factors that are not previously reported must be considered with prudence until their validation. This limitation points to the necessity of using larger cohorts in studies involving a pre-dementia stage.
Efforts are required to provide useful data, which can help in designing strategies to stop or modulate the course of the disease. In that sense, a GWAS in the MCI population seems mandatory. Moreover, the identification of the genetic factors conferring resilience to dementia in non-demented people could provide a good opportunity in uncovering the compensatory mechanisms that may prevent the disease progression. Therefore, a genome-wide approach for endophenotypes involved in CR also seems affordable and advisable.
In conclusion, genetic research in the pre-dementia stages of non-demented people must be potentiated to obtain advances in AD and design prevention strategies.
